MORF - Morphic Therapeutic - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

2.18B

Cash

658.8M

Avg Qtr Burn

-31.81M

Short % of Float

4.98%

Insider Ownership

17.27%

Institutional Own.

99.33%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MORF-057 (α4β7 integrin) Details Ulcerative colitis	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MORF-057 (α4β7 integrin) Details Crohns disease	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.